Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

RCT (472) found oral azacitidine provided a significantly increased overall survival and relapse free survival vs placebo (24.7 months vs 14.8 months, and 10.2 months vs 4.8 months respectively, p<0.001 for both). Neutropenia was more common with azacitidine (41% vs 24%).

New England Journal of Medicine